Clinical diagnostics for organ transplants developer VericiDx (LON: VRCI) reported a rise in interim loss from $1.3m to $3.1m after a 43% decline in revenues to $1.9m. The company does have two commercial products and full year revenues are expected to rise to $4.14m. The share price rebounded 28% to 0.8p.
Video marketing platform operator SEEEN (LON: SEEN) increased first half revenues by 87% to $2.1m and full year revenues are expected to be more than £5m, helped by a significant deal signed earlier in the year. The full year loss should be reduced by three-quarters to £400,000 and the company could breakeven next year. Net cash was $1.2m at the end of June 2025. The share price increased 11.1% to 5p.
Gunsynd (LON: GUN) says assay results from the Bear Twit project have been sent to the lab and results should be received in October. Exploration continues at the Barb gold project. The share price improved 10% to 0.165p.
Carpet tiles manufacturer Airea (LON: AIEA) managed to increase first half revenues, while progressing the move to a new facility. Revenues improved from £9.23m to £9.82m, which is about as much as can be achieved in the current factory. The main growth was in the UK and Ireland, despite the weak market. There was a £44,000 loss after costs of setting up in Dubai and storage ahead of the move. Additional capital investment means that the move will be at the start of 2026. Even after the capital expenditure, net cash was £1.14m at the end of June 2025, although that excludes a similar amount of supply chain finance. An investment property valued at £4.1m may be sold. The share price rose 8.7% to 25p.
FALLERS
Difficult market conditions hampered regenerative medicine company Tissue Regenix (LON: TRX) and interim revenues were 6% down at $13.8m. That hit gross margin and the loss increased to $957,000. There were delays to regulatory approvals and falls in orders. Net debt is $9.3m with $5.6m of available bank facilities. The share price slumped 40.5% to 12.5p.
Steel structures supplier Billington (LON: BILN) has been hit by delays just like many other companies involved in the construction sector. It has won business to help cover for the delays, but margins are not as high. Interim revenues fell from £57.9m to £41.8m, while pre-tax profit slipped from £4.64m to £1.67m. Cavendish has halved its full year pe-tax profit forecast to £3.5m. The order book covers around 50% of forecast 2026 revenues and pre-tax profit could rebound to £8.3m. The share price declined 13.9% to 280p, which is less than seven times prospective 2026 earnings.
Health assessment technology developer GENinCode (LON: GENI) reported interims in line with its recent trading statement. Revenues rose 15% to £1.6m and the loss was similar to the previous year. Cash was £2.44m at the end of June 2024. Cavendish has cut its forecast 2025 revenues from £4.3m to £3.3m, while the loss is expected to be £4.7m. The share price fell back 14.3% to 3.6p, but it has doubled in the past fortnight.
Wishbone Gold (LON: WSBN) is raising £4m at 1.3p/share. This will fund further exploration at the Red Setter Gold Dome in Australia. The previous placing was at 0.13p/share. Interim results show a cash outflow of £1.3m, leaving cash of £826,000 at the end of June 2025. The share price slipped 13.3% to 1.265p.